A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Amikacin (Primary) ; Antibacterials
- Indications Gram-negative infections; Nosocomial pneumonia
- Focus Registrational; Therapeutic Use
- Acronyms INHALE-2
- Sponsors Bayer
- 07 Dec 2017 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 24 Nov 2017 According to a Bayer media release, the primary as well as secondary endpoints of the INHALE phase III program were not met. Efficacy and safety analyses from this study will be published in due course.
- 05 May 2017 Status changed from recruiting to completed.